Sell 2/23/2023Upgraded
Olema Pharmaceuticals, Inc. (OLMA) was upgraded to D- from E+ on 2/23/2023 due to an increase in the total return index and volatility index.

Sell 2/8/2023Downgrade
Olema Pharmaceuticals, Inc. (OLMA) was downgraded to E+ from D- on 2/8/2023 due to a decline in the growth index and solvency index. The quick ratio declined from 19.56 to 17.77.

Sell 5/11/2022Upgraded
Olema Pharmaceuticals, Inc. (OLMA) was upgraded to D- from E+ on 5/11/2022 due to an increase in the growth index. Operating cash flow increased 3.76% from -$18.6M to -$17.9M.

Sell 4/20/2022Downgrade
Olema Pharmaceuticals, Inc. (OLMA) was downgraded to E+ from D- on 4/20/2022 due to a decline in the volatility index and total return index.

Sell 2/17/2022Upgraded
Olema Pharmaceuticals, Inc. (OLMA) was upgraded to D- from E+ on 2/17/2022 due to an increase in the volatility index and valuation index.

Sell 2/2/2022Downgrade
Olema Pharmaceuticals, Inc. (OLMA) was downgraded to E+ from D- on 2/2/2022 due to a decline in the total return index and volatility index.

Sell 11/15/2021Downgrade
Olema Pharmaceuticals, Inc. (OLMA) was downgraded to D- from D on 11/15/2021 due to a substantial decline in the efficiency index, growth index and solvency index. The quick ratio declined from 61.96 to 34.37, net income declined 15.48% from -$15.34M to -$17.71M, and EBIT declined 14.96% from -$15.45M to -$17.76M.

Sell 5/20/2021Upgraded
Olema Pharmaceuticals, Inc. (OLMA) was upgraded to D from E on 05/20/2021.

Sell 5/12/2021None
Olema Pharmaceuticals, Inc. (OLMA) was downgraded to E from U on 05/12/2021.